echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Puli Pharmaceuticals: Bivarudin for injection successfully challenged the US patent

    Puli Pharmaceuticals: Bivarudin for injection successfully challenged the US patent

    • Last Update: 2021-03-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 2, Puli Pharmaceuticals announced that the company obtained the FDA's provisional approval for bivalerudin for injection in December 2020, and in January 2021, it will issue a marketing license and patent holder for the original formulation of the product.


    It is understood that Bivarudine is a synthetic anticoagulant drug.


    At the same time, Puli Pharmaceuticals has notified the FDA of the above-mentioned progress and has submitted an application for final approval of the generic bivalrudine for injection.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.